{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T02:59:10Z","timestamp":1767495550051,"version":"3.48.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Diabetes Metab Disord"],"DOI":"10.1007\/s40200-025-01757-8","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T14:38:15Z","timestamp":1760452695000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Metabolic dysfunction\u2013associated steatotic liver disease in individuals with type 2 diabetes mellitus and diabetic foot ulcers: prevalence and associated factors"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1271-6298","authenticated-orcid":false,"given":"H\u00fcseyin","family":"Karaaslan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2534-8607","authenticated-orcid":false,"given":"Ensar Gazi","family":"G\u00f6\u00e7er","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9507-6670","authenticated-orcid":false,"given":"Ferit","family":"Do\u011fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"issue":"6","key":"1757_CR1","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/apt.17158","volume":"56","author":"L Henry","year":"2022","unstructured":"Henry L, Paik J, Younossi ZM. Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world. Aliment Pharmacol Ther. 2022;56(6):942\u201356. https:\/\/doi.org\/10.1111\/apt.17158.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"1757_CR2","doi-asserted-by":"publisher","first-page":"211","DOI":"10.4291\/wjgp.v7.i2.211","volume":"7","author":"S Alam","year":"2016","unstructured":"Alam S, Mustafa G, Alam M, Ahmad N. Insulin resistance in development and progression of nonalcoholic fatty liver disease. World J Gastrointest Pathophysiol. 2016;7(2):211\u20137. https:\/\/doi.org\/10.4291\/wjgp.v7.i2.211.","journal-title":"World J Gastrointest Pathophysiol"},{"issue":"1","key":"1757_CR3","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202\u20139. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.039.","journal-title":"J Hepatol"},{"doi-asserted-by":"publisher","unstructured":"Rinella ME, Lazarus JV, Ratziu V, NAFLD nomenclature consensus group, et al. A multisociety delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966\u201386. https:\/\/doi.org\/10.1097\/HEP.0000000000000520.","key":"1757_CR4","DOI":"10.1097\/HEP.0000000000000520"},{"issue":"4","key":"1757_CR5","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","volume":"71","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71(4):793\u2013801. https:\/\/doi.org\/10.1016\/j.jhep.2019.06.021.","journal-title":"J Hepatol"},{"doi-asserted-by":"publisher","unstructured":"En Li Cho, Ang CZ, Quek J, et al. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. Gut. 2023;72(11):2138\u201348. https:\/\/doi.org\/10.1136\/gutjnl-2023-330110.","key":"1757_CR6","DOI":"10.1136\/gutjnl-2023-330110"},{"key":"1757_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2337\/db20182-1","volume":"2018","author":"AJM Boulton","year":"2018","unstructured":"Boulton AJM, Armstrong DG, Krisner RS, et al. Diagnosis and management of diabetic foot complications. Compendia. 2018;2018:1\u201320.","journal-title":"Compendia"},{"issue":"1","key":"1757_CR8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41387-024-00290-6","volume":"14","author":"Q Ran","year":"2024","unstructured":"Ran Q, Xu W, Zhao X, Sun H, Liu L, Luo Y. Risk factors for malnutrition in patients with diabetic foot ulcer and its association with prolonged length of hospitalization. Nutr Diabetes. 2024;14(1):26. https:\/\/doi.org\/10.1038\/s41387-024-00290-6.","journal-title":"Nutr Diabetes"},{"issue":"1","key":"1757_CR9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3892\/etm.2012.780","volume":"5","author":"SS Zhang","year":"2013","unstructured":"Zhang SS, Tang ZY, Fang P, Qian HJ, Xu L, Ning G. Nutritional status deteriorates as the severity of diabetic foot ulcers increases and independently associates with prognosis. Exp Ther Med. 2013;5(1):215\u201322. https:\/\/doi.org\/10.3892\/etm.2012.780.","journal-title":"Exp Ther Med"},{"issue":"4","key":"1757_CR10","doi-asserted-by":"publisher","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","volume":"145","author":"AS Levey","year":"2006","unstructured":"Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247\u201354. https:\/\/doi.org\/10.7326\/0003-4819-145-4-200608150-00004.","journal-title":"Ann Intern Med"},{"issue":"5","key":"1757_CR11","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.jvs.2023.07.020","volume":"78","author":"R Fitridge","year":"2023","unstructured":"Fitridge R, Chuter V, Mills J, et al. The intersocietal IWGDF, ESVS, SVS guidelines on peripheral artery disease in people with diabetes mellitus and a foot ulcer. J Vasc Surg. 2023;78(5):1101\u201331. https:\/\/doi.org\/10.1016\/j.jvs.2023.07.020.","journal-title":"J Vasc Surg"},{"issue":"4S","key":"1757_CR12","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117\u2013314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018.","journal-title":"Kidney Int"},{"issue":"3","key":"1757_CR13","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1053\/gast.2002.35354","volume":"123","author":"S Saadeh","year":"2002","unstructured":"Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123(3):745\u201350. https:\/\/doi.org\/10.1053\/gast.2002.35354.","journal-title":"Gastroenterology"},{"issue":"1","key":"1757_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cmet.2021.12.012","volume":"34","author":"S Klein","year":"2022","unstructured":"Klein S, Gastaldelli A, Yki-J\u00e4rvinen H, Scherer PE. Why does obesity cause diabetes? Cell Metab. 2022;34(1):11\u201320. https:\/\/doi.org\/10.1016\/j.cmet.2021.12.012.","journal-title":"Cell Metab"},{"key":"1757_CR15","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2147\/CEOR.S157673","volume":"10","author":"M DiBonaventura","year":"2018","unstructured":"DiBonaventura M, Nicolucci A, Meincke H, Le Lay A, Fournier J. Obesity in Germany and Italy: prevalence, comorbidities, and associations with patient outcomes. Clinicoecon Outcomes Res. 2018;10:457\u201375. https:\/\/doi.org\/10.2147\/CEOR.S157673.","journal-title":"Clinicoecon Outcomes Res"},{"key":"1757_CR16","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2147\/DMSO.S51325","volume":"6","author":"AD Colosia","year":"2013","unstructured":"Colosia AD, Palencia R, Khan S. Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature review. Diabetes Metab Syndr Obes. 2013;6:327\u201338. https:\/\/doi.org\/10.2147\/DMSO.S51325.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"1","key":"1757_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0144179","volume":"11","author":"X Zhou","year":"2016","unstructured":"Zhou X, Ji L, Ran X, et al. Prevalence of obesity and its influence on achievement of cardiometabolic therapeutic goals in Chinese type 2 diabetes patients: an analysis of the Nationwide, Cross-Sectional 3B study. PLoS ONE. 2016;11(1):e0144179. https:\/\/doi.org\/10.1371\/journal.pone.0144179.","journal-title":"PLoS ONE"},{"issue":"1","key":"1757_CR18","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1080\/07853890.2023.2182909","volume":"55","author":"E Ekpor","year":"2023","unstructured":"Ekpor E, Akyirem S, Adade Duodu P. Prevalence and associated factors of overweight and obesity among persons with type 2 diabetes in Africa: a systematic review and meta-analysis. Ann Med. 2023;55(1):696\u2013713. https:\/\/doi.org\/10.1080\/07853890.2023.2182909.","journal-title":"Ann Med"},{"issue":"1","key":"1757_CR19","doi-asserted-by":"publisher","first-page":"143","DOI":"10.4103\/jfmpc.jfmpc_1349_20","volume":"10","author":"MS AlShahrani","year":"2021","unstructured":"AlShahrani MS. Prevalence of obesity and overweight among type 2 diabetic patients in Bisha, Saudi Arabia. J Fam Med Prim Care. 2021;10(1):143\u20138. https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_1349_20.","journal-title":"J Fam Med Prim Care"},{"key":"1757_CR20","first-page":"85","volume":"6","author":"A Marjani","year":"2011","unstructured":"Marjani A. Prevalence of obesity among type 2 diabetes mellitus in Gorgan (South East of Caspian Sea), Iran. J Chin Clin Med. 2011;6:85\u201392.","journal-title":"J Chin Clin Med"},{"issue":"1","key":"1757_CR21","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1590\/s1020-49892007000600002","volume":"22","author":"G Lopez Stewart","year":"2007","unstructured":"Lopez Stewart G, Tambascia M, Rosas Guzm\u00e1n J, Etchegoyen F, Ortega Carri\u00f3n J, Artemenko S. Control of type 2 diabetes mellitus among general practitioners in private practice in nine countries of Latin America. Rev Panam Salud Publica. 2007;22(1):12\u201320. https:\/\/doi.org\/10.1590\/s1020-49892007000600002.","journal-title":"Rev Panam Salud Publica"},{"issue":"5","key":"1757_CR22","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.dsx.2020.05.043","volume":"14","author":"NC do Vale Moreira","year":"2020","unstructured":"do Vale Moreira NC, Hussain A, Bhowmik B, et al. Prevalence of metabolic syndrome by different definitions, and its association with type 2 diabetes, pre-diabetes, and cardiovascular disease risk in Brazil. Diabetes Metab Syndr. 2020;14(5):1217\u201324. https:\/\/doi.org\/10.1016\/j.dsx.2020.05.043.","journal-title":"Diabetes Metab Syndr"},{"key":"1757_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.818816","volume":"10","author":"RA Nianogo","year":"2022","unstructured":"Nianogo RA, Arah OA. Forecasting obesity and type 2 diabetes incidence and burden: the ViLA-obesity simulation model. Front Public Health. 2022;10:818816. https:\/\/doi.org\/10.3389\/fpubh.2022.818816.","journal-title":"Front Public Health"},{"unstructured":"U.S. Centers for Disease Control and Prevention. National Diabetes Statistics Report. Updated 2024. Accessed May 15, 2024. https:\/\/www.cdc.gov\/diabetes\/php\/data-research\/index.html","key":"1757_CR24"},{"issue":"2","key":"1757_CR25","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s10654-013-9771-5","volume":"28","author":"I Satman","year":"2013","unstructured":"Satman I, Omer B, Tutuncu Y, TURDEP-II Study Group, et al. Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. Eur J Epidemiol. 2013;28(2):169\u201380. https:\/\/doi.org\/10.1007\/s10654-013-9771-5.","journal-title":"Eur J Epidemiol"},{"issue":"5","key":"1757_CR26","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.pcd.2019.12.006","volume":"14","author":"S Ak\u0131n","year":"2020","unstructured":"Ak\u0131n S, B\u00f6l\u00fck C. Prevalence of comorbidities in patients with type-2 diabetes mellitus. Prim Care Diabetes. 2020;14(5):431\u20134. https:\/\/doi.org\/10.1016\/j.pcd.2019.12.006.","journal-title":"Prim Care Diabetes"},{"issue":"10","key":"1757_CR27","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1086\/587658","volume":"46","author":"P Katona","year":"2008","unstructured":"Katona P, Katona-Apte J. The interaction between nutrition and infection. Clin Infect Dis. 2008;46(10):1582\u20138. https:\/\/doi.org\/10.1086\/587658.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1757_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/nu13010183","volume":"13","author":"A Izzo","year":"2021","unstructured":"Izzo A, Massimino E, Riccardi G, Della Pepa G. A narrative review on sarcopenia in type 2 diabetes mellitus: prevalence and associated factors. Nutrients. 2021;13(1):183. https:\/\/doi.org\/10.3390\/nu13010183.","journal-title":"Nutrients"},{"issue":"1","key":"1757_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-022-00980-1","volume":"22","author":"S Pouwels","year":"2022","unstructured":"Pouwels S, Sakran N, Graham Y, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022;22(1):63. https:\/\/doi.org\/10.1186\/s12902-022-00980-1.","journal-title":"BMC Endocr Disord"},{"issue":"10","key":"1757_CR30","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.tem.2019.07.013","volume":"30","author":"NN El-Agroudy","year":"2019","unstructured":"El-Agroudy NN, Kurzbach A, Rodionov RN, et al. Are lifestyle therapies effective for NAFLD treatment? Trends Endocrinol Metab. 2019;30(10):701\u20139. https:\/\/doi.org\/10.1016\/j.tem.2019.07.013.","journal-title":"Trends Endocrinol Metab"},{"issue":"2","key":"1757_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24021703","volume":"24","author":"R Nevola","year":"2023","unstructured":"Nevola R, Epifani R, Imbriani S, et al. GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives. Int J Mol Sci. 2023;24(2):1703. https:\/\/doi.org\/10.3390\/ijms24021703.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1757_CR32","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3892\/br.2018.1100","volume":"9","author":"H Wang","year":"2018","unstructured":"Wang H, Wang L, Cheng Y, Xia Z, Liao Y, Cao J. Efficacy of Orlistat in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Biomed Rep. 2018;9(1):90\u20136. https:\/\/doi.org\/10.3892\/br.2018.1100.","journal-title":"Biomed Rep"},{"issue":"24","key":"1757_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10245721","volume":"10","author":"P G\u0142uszy\u0144ska","year":"2021","unstructured":"G\u0142uszy\u0144ska P, Lemancewicz D, Dzi\u0119cio\u0142 JB, Razak Hady H. Non-alcoholic fatty liver disease (NAFLD) and bariatric\/metabolic surgery as its treatment option: a review. J Clin Med. 2021;10(24):5721. https:\/\/doi.org\/10.3390\/jcm10245721.","journal-title":"J Clin Med"},{"key":"1757_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101111","volume":"50","author":"W Jonas","year":"2021","unstructured":"Jonas W, Sch\u00fcrmann A. Genetic and epigenetic factors determining NAFLD risk. Mol Metab. 2021;50:101111. https:\/\/doi.org\/10.1016\/j.molmet.2020.101111.","journal-title":"Mol Metab"},{"issue":"4","key":"1757_CR35","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.dsx.2018.03.016","volume":"12","author":"HM Al-Dayyat","year":"2018","unstructured":"Al-Dayyat HM, Rayyan YM, Tayyem RF. Non-alcoholic fatty liver disease and associated dietary and lifestyle risk factors. Diabetes Metab Syndr. 2018;12(4):569\u201375. https:\/\/doi.org\/10.1016\/j.dsx.2018.03.016.","journal-title":"Diabetes Metab Syndr"},{"issue":"648","key":"1757_CR36","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abk0855","volume":"14","author":"H Leung","year":"2022","unstructured":"Leung H, Long X, Ni Y, et al. Risk assessment with gut microbiome and metabolite markers in NAFLD development. Sci Transl Med. 2022;14(648):eabk0855. https:\/\/doi.org\/10.1126\/scitranslmed.abk0855.","journal-title":"Sci Transl Med"},{"issue":"1","key":"1757_CR37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11\u201320. https:\/\/doi.org\/10.1038\/nrgastro.2017.109.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"8","key":"1757_CR38","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1111\/liv.14943","volume":"41","author":"P Burra","year":"2021","unstructured":"Burra P, Bizzaro D, Gonta A, et al. Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Liver Int. 2021;41(8):1713\u201333. https:\/\/doi.org\/10.1111\/liv.14943.","journal-title":"Liver Int"},{"key":"1757_CR39","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.2147\/CIA.S295524","volume":"16","author":"SA Alqahtani","year":"2021","unstructured":"Alqahtani SA, Schattenberg JM. NAFLD in the elderly. Clin Interv Aging. 2021;16:1633\u201349. https:\/\/doi.org\/10.2147\/CIA.S295524.","journal-title":"Clin Interv Aging"},{"issue":"8","key":"1757_CR40","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.metabol.2016.05.003","volume":"65","author":"N Katsiki","year":"2016","unstructured":"Katsiki N, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: an update. Metabolism. 2016;65(8):1109\u201323. https:\/\/doi.org\/10.1016\/j.metabol.2016.05.003.","journal-title":"Metabolism"},{"issue":"4","key":"1757_CR41","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.jhep.2020.01.013","volume":"72","author":"CD Byrne","year":"2020","unstructured":"Byrne CD, Targher G. NAFLD as a driver of chronic kidney disease. J Hepatol. 2020;72(4):785\u2013801. https:\/\/doi.org\/10.1016\/j.jhep.2020.01.013.","journal-title":"J Hepatol"},{"issue":"11","key":"1757_CR42","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.dld.2018.08.012","volume":"50","author":"Z Guo","year":"2018","unstructured":"Guo Z, Li M, Han B, Qi X. Association of non-alcoholic fatty liver disease with thyroid function: a systematic review and meta-analysis. Dig Liver Dis. 2018;50(11):1153\u201362. https:\/\/doi.org\/10.1016\/j.dld.2018.08.012.","journal-title":"Dig Liver Dis"},{"issue":"1","key":"1757_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-020-1165-z","volume":"20","author":"X Ma","year":"2020","unstructured":"Ma X, Liu S, Zhang J, et al. Proportion of NAFLD patients with normal ALT value in overall NAFLD patients: a systematic review and meta-analysis. BMC Gastroenterol. 2020;20(1):10. https:\/\/doi.org\/10.1186\/s12876-020-1165-z.","journal-title":"BMC Gastroenterol"}],"container-title":["Journal of Diabetes & Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40200-025-01757-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40200-025-01757-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40200-025-01757-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T02:55:51Z","timestamp":1767495351000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40200-025-01757-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":43,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1757"],"URL":"https:\/\/doi.org\/10.1007\/s40200-025-01757-8","relation":{},"ISSN":["2251-6581"],"issn-type":[{"type":"electronic","value":"2251-6581"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"14 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Harran University ethics committee (approval number: HRU\/23\/14\/36, dated August 7, 2023).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"228"}}